REVIVA PHARMACEUTICALS HOLDINGS, INC. Quarterly Operating Income (Loss) in USD from Q2 2018 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Reviva Pharmaceuticals Holdings, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q2 2018 to Q2 2024.
  • Reviva Pharmaceuticals Holdings, Inc. Operating Income (Loss) for the quarter ending June 30, 2024 was -$8.13M, a 28.3% increase year-over-year.
  • Reviva Pharmaceuticals Holdings, Inc. Operating Income (Loss) for the twelve months ending June 30, 2024 was -$37.2M, a 10.9% decline year-over-year.
  • Reviva Pharmaceuticals Holdings, Inc. annual Operating Income (Loss) for 2023 was -$39.5M, a 39.9% decline from 2022.
  • Reviva Pharmaceuticals Holdings, Inc. annual Operating Income (Loss) for 2022 was -$28.2M, a 179% decline from 2021.
  • Reviva Pharmaceuticals Holdings, Inc. annual Operating Income (Loss) for 2021 was -$10.1M, a 315% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 -$37.2M -$8.13M +$3.21M +28.3% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-14
Q1 2024 -$40.4M -$7.92M -$937K -13.4% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-14
Q4 2023 -$39.5M -$9.62M +$142K +1.45% Oct 1, 2023 Dec 31, 2023 10-K 2024-04-15
Q3 2023 -$39.6M -$11.6M -$6.07M -110% Jul 1, 2023 Sep 30, 2023 10-K 2024-04-15
Q2 2023 -$33.6M -$11.3M -$5.82M -105% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-14
Q1 2023 -$27.8M -$6.98M +$465K +6.25% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-14
Q4 2022 -$28.2M -$9.76M -$5.8M -146% Oct 1, 2022 Dec 31, 2022 10-K 2024-04-15
Q3 2022 -$22.4M -$5.5M -$3.02M -122% Jul 1, 2022 Sep 30, 2022 10-K 2024-04-15
Q2 2022 -$19.4M -$5.52M -$3.73M -208% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-14
Q1 2022 -$15.7M -$7.45M -$5.58M -298% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-15
Q4 2021 -$10.1M -$3.97M -$3.61M -1027% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-30
Q3 2021 -$6.49M -$2.48M -$1.96M -383% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-14
Q2 2021 -$4.53M -$1.79M -$1.01M -130% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-15
Q1 2021 -$3.51M -$1.87M -$1.25M -203% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-16
Q4 2020 -$2.26M -$352K -$186K -112% Sep 1, 2020 Nov 30, 2020 10-Q 2021-01-14
Q3 2020 -$2.07M -$512K -$418K -444% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-15
Q2 2020 -$1.66M -$777K -$706K -993% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-16
Q1 2020 -$950K -$618K -$560K -966% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-17
Q4 2019 -$389K -$166K -$86.9K -110% Sep 1, 2019 Nov 30, 2019 10-Q 2021-01-14
Q3 2019 -$302K -$94.1K -$91.8K Jun 1, 2019 Aug 31, 2019 10-Q 2020-10-14
Q2 2019 -$211K -$71.1K -$57.8K -433% Mar 1, 2019 May 31, 2019 10-Q 2020-07-07
Q1 2019 -$153K -$58K Dec 1, 2018 Feb 28, 2019 10-K 2020-05-04
Q4 2018 -$79.1K Sep 1, 2018 Nov 30, 2018 10-Q 2020-01-10
Q3 2018 -$2.33K* Jun 1, 2018 Aug 31, 2018 10-Q 2019-10-08
Q2 2018 -$13.3K Mar 20, 2018 May 31, 2018 10-Q 2019-07-03
* An asterisk sign (*) next to the value indicates that the value is likely invalid.